Rodion V. Ponomarev

Rodion V. Ponomarev

Auto-generated profile, based on publicly available information

Rodion V. Ponomarev

National Medical Research Center for Hematology

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2025 in Primary Health Care (Russian Federation)
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
OTO. N. Tkacheva
O. N. Tkacheva
ESEvgenia Shikh
Evgenia Shikh
LDL. Yu. Drozdova
L. Yu. Drozdova
IBI. I. Baranov
I. I. Baranov
NKN. O. Khovasova
N. O. Khovasova
At the Expert Council meeting, key issues related to the prevention of latent iron deficiency (LID) and iron deficiency anemia (IDA) in at-risk populations were discussed, including women of reproductive age, pregnant women, blood donors, and patients with chronic diseases. Participants reviewed international and national guidelines, acceptable levels of iron intake, as well as barriers limiting the implementation of standard preventive approaches in clinical practice. Particular attention was given to chelated forms of iron, especially iron bisglycinate, noted for its high bioavailability and favorable tolerability profile. The experts emphasized the importance of using formulations containing components that enhance iron absorption and metabolism. Following the discussion, a resolution was adopted reflecting the consolidated interdisciplinary position of specialists on the prevention of LID and IDA, including patient management algorithms, care pathways, risk group identification, and recommendations for improving the regulatory framework.

10 August 2019 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
АСА. А. Соловьева
А. А. Соловьева
GYG. A. Yatsyk
G. A. Yatsyk
RPR. V. Ponomarev
R. V. Ponomarev
KLK. A. Lukina
K. A. Lukina
IKI. E. Kostina
I. E. Kostina
ELE. A. Lukina
E. A. Lukina
Background. Gaucher disease is an autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme glucocerebrosidase, which is required for the degradation of glycosphingolipids. Skeletal involvement is one of the main manifestations of the disease and is present in 70–100 % of patients. However, the rarity of Gaucher disease and non-specific and heterogeneous nature of its symptoms and radiological signs may impede consideration of this disease in the differential diagnosis.Aim. To describe the radiological signs of bone involvement in type I Gaucher disease and assess the role of MRI in the evaluation of the severity of the disease in newly diagnosed patients.Materials and methods. X-ray and MRI data of 86 treatment-naïve Gaucher patients were included in the retrospective analysis. Bone marrow involvement, as well as bone and joint pathological changes, were evaluated.Results. Radiological signs of bone involvement in Gaucher patients were described and classified into 2 groups, i.e. reversible and irreversible. Such a classification is important in terms of the assessment of the overall disease severity. MRI has proven to be a sensitive method for detection and evaluation of the reversible bone changes in Gaucher patients.Conclusion. Although radiological manifestations of bone involvement in Gaucher patients are typical, they may significantly vary and be present in various combinations. MRI is the gold standard for the assessment of bone marrow changes in patients with Gaucher disease.

27 January 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
VLV. D. Latyshev
V. D. Latyshev
ZFZ. T. Fidarova
Z. T. Fidarova
RPR. V. Ponomarev
R. V. Ponomarev
NTN. V. Tsvetaeva
N. V. Tsvetaeva
EME. A. Mikhaylova
E. A. Mikhaylova
EPE. N. Parovichnikova
E. N. Parovichnikova
Background. Paroxysmal nocturnal hemoglobinuria is a rare clonal disease of the hematopoietic system, with the key manifestations of hemolytic anemia, a high thrombosis rate, and bone marrow failure. Despite the high efficacy of C5‑inhibitors in intravascular hemolysis cessation, a significant proportion of patients remain anemic. Causes of a sub‑optimal response may include C3‑mediated extravascular (intracellular) hemolysis, residual intravascular hemolysis, or bone marrow failure.Aim. To analyze the results of pathogenetic therapy in patients with paroxysmal nocturnal hemoglobinuria.Materials and methods. The study included 55 patients with paroxysmal nocturnal hemoglobinuria receiving complement C5 inhibitors for at least 6 months. Results. Suboptimal hematological response was observed in 31/55 (56 %) patients. The most common cause of anemia in the partial response group was C3‑mediated extravascular hemolysis in 8/10 (80 %), while bone marrow failure predominated (57 %) in the minor response group.Conclusion. The study showed a high frequency of suboptimal response to pathogenetic therapy and necessity of ac‑curate determination of leading cause of persistent anemia in order to modify therapy or switch to other drugs.

9 November 2019 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
RPR. V. Ponomarev
R. V. Ponomarev
KLK. A. Lukina
K. A. Lukina
ESE. P. Sysoeva
E. P. Sysoeva
RCR. B. Chavynchak
R. B. Chavynchak
ASA. A. Solovyeva
A. A. Solovyeva
ELE. A. Lukina
E. A. Lukina
Introduction. Gaucher disease (GD) belongs to the group of lysosomal storage diseases. Enzyme replacement therapy (ERT) is considered to be the current standard in GD treatment. No reduced ERT regimen has thus far been developed. Aim. To develop an optimal reduced ERT regimen for adult patients with type I GD, which is scientifically and economically viable.Materials and methods. The study included 100 adult patients with type I GD who achieved treatment goals following at least two years of the standard ERT regimen. Patients were prescribed a reduced ERT regimen, which consisted in increasing the interval between the infusions of the recombinant enzyme up to 4 weeks, at a dose of 15–20 units/kg of body weight. The efficacy of the reduced ERT regimen was assessed once every 12 months according to main GD parameters. The follow-up period in the study ranged from 12 to 36 months.Results. The patients with type I GD who achieved treatment goals following the standard ERT regimen and were then prescribed a reduced ERT regimen retained a stable therapeutic effect of the initial treatment according to all parameters: no clinically significant differences found in haemoglobin and platelet levels, spleen size and specific infiltration of femur bone marrow.Conclusion. An increase in the intervals between infusions of the recombinant glucocerebrosidase up to 4 weeks for 12, 24 and 36 months did not lead to worsening of the laboratory and instrumental parameters associated with GD.

7 June 2024 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
MSMarina Shestakova
Marina Shestakova
AAAlexander Ametov
Alexander Ametov
MAMikhail Antsiferov
Mikhail Antsiferov
IBIgor G. Bakulin
Igor G. Bakulin
MSMinara Shamkhalova
Minara Shamkhalova
On March 20, 2024, an interdisciplinary meeting of the Expert Council on the current problem of B12 insufficiency/deficiency and the prevalence of this condition among endocrine patients was held at the Endocrinology Research Centre (Moscow). The purpose of the meeting was to assess the role of B12 deficiency in reducing the quality of life of patients of different groups and to outline a strategy for the management of patients with vitamin B12 insufficiency/deficiency by endocrinologists.The resolution of the expert council was developed by leading specialists in various specialties.

11 March 2020 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
ESE. P. Sysoeva
E. P. Sysoeva
RPR. V. Ponomarev
R. V. Ponomarev
KLK. A. Lukina
K. A. Lukina
RCR. B. Chavynchak
R. B. Chavynchak
SKS. B. Korotkova
S. B. Korotkova
ELE. A. Lukina
E. A. Lukina
Background. Gaucher disease (GD) is a rare hereditary condition, which represents the most common form of lysosomal storage diseases. Enzyme replacement therapy (ERT) with recombinant glucocerebrosidase is used for the treatment of type 1 and type 3 GD. Imiglucerase (recombinant glucocerebrosidase) is the first biotechnological ERT medication possessing confirmed clinical efficacy and safety.Aim. To compare the efficacy and safety of the biosimilar drug Glurazyme and the reference drug Cerezyme during ERT therapy in patients with type 1 GD.Materials and methods. Thirty patients aged from 19 to 63 years (33 ± 9.7 years) with a stable course of type 1 GD were enrolled in the study. The patients were randomly divided into two equal treatment groups, one of which received Glurazyme and the other received the reference drug Cerezyme. In both groups, the drugs were used in doses of 15–40 U/kg intravenously once every 14 days for 52 weeks.Results. At the end of the study, at week 52 (primary endpoint of efficacy), both groups demonstrated a similar increase in hemoglobin concentration compared to the baseline data. In both groups, the average increase in hemoglobin concentration was 4.8 g/l, with this parameter varying between the groups by 0.1 g/l. At week 52, the calculated 95% confidence interval for the difference in hemoglobin concentration did not cross the non-inferiority margin of 18 g/l, which had been specified as the lower level of drug efficacy. This led to the conclusion that the studied drug Glurazyme is not inferior to Cerezyme in terms of efficacy. A comparison of the treatment groups by secondary endpoints of efficacy revealed: no decrease in hemoglobin concentration by more than 20 % in both groups; no differences between the groups by the number of patients with a change in platelet concentration relative to the baseline values; no increase in the spleen and liver volume by more than 20 and 10 %, respectively, in both groups. The doses of the drug under study and the reference drug remained unchanged during the research. The concentration of chemokine CCL-18 decreased slightly in 10 patients (64.3 %) and 6 patients (40 %) in the Glurazyme group and the Cerezyme group, respectively. The proportion of patients with improved physical and mental health components was 57.1 and 57.1 %, respectively, in the Glurazyme group compared to 73.3 and 60 %, respectively, in the Cerezyme group. Changes in the state of the bone tissue and the reserves of accumulated metabolites in the bone marrow showed a similar decrease in the severity of bone marrow infiltration in both groups.Conclusions. Glurazyme and Cerezyme showed comparable parameters of efficacy and safety in patients with GD type 1 during long-term enzyme replacement therapy.